



**Proteomics International**

LABORATORIES LTD

**ASX Release**  
**10 June 2021**

**ASX code: PIQ**

## **CCO and CFO appointed to bolster executive team**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) today announced the expansion of its executive team with the appointments of Vik Malik as its new Chief Commercialisation Officer (CCO) and Jacqueline Gray as its new Chief Financial Officer (CFO).

A worldwide executive search was undertaken in preparation for what is set to be a transformative period for Proteomics International.

Medical Technologies commercialisation veteran Vik Malik will lead Proteomics International's commercial roll-out of the Company's innovative diagnostic products centred on the PromarkerD predictive test for diabetic kidney disease. Starting 1<sup>st</sup> June, he will initially be based in the USA. Mr Malik has an extensive network of clinical (KOL) and business professionals in the healthcare, medical device and diagnostics sectors, which will prove invaluable as Proteomics International ramps up the commercialisation of PromarkerD in the US and Europe.

Jacqueline Gray is a well-credentialed finance professional with experience across global brands including in the technology, healthcare and media sectors. Effective 12<sup>th</sup> July 2021, Ms Gray will have responsibility for Proteomics International's finance, accounting and financial strategy development.

Proteomics International Managing Director Dr Richard Lipscombe said he was very pleased to welcome Mr Malik and Ms Gray to the newly-created roles.

*"With the assistance of renowned global recruitment companies, we conducted an exhaustive search for the ideal executives to bring in for our next stage of growth. Vik and Jacqueline have a wealth of expertise in their respective specialities, and have extensive experience in fast-growing companies similar to Proteomics International. We are delighted to appoint them to these new positions. Their knowledge and experience will further bolster our executive team and will help drive our Company's growth globally."*

Mr Malik said he is excited to have the opportunity to bring the ground-breaking PromarkerD test to global markets and change the standard of care for patients worldwide. Ms Gray said that this is an exciting time to join Proteomics International as the Company accelerates its next phase of expansion.

### **Chief Commercialisation Officer: Vik Malik**

Mr Malik has more than 20 years' experience in the life sciences and healthcare industries as a commercialisation expert and business strategy advisor for several multinational, growth-stage and startup medical device and diagnostics companies.

Mr Malik has been involved in the launch of numerous disruptive medical technologies, cutting-edge biotherapies, innovative healthcare IT solutions and customised business process outsourcing services to penetrate new and emerging markets.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Most recently, Mr Malik served as Chief Executive Officer and board director for surgical software startup ClaraSim Systems (USA), and has previously held senior leadership positions with IQVIA (IMS Health + Quintiles), BioFuse Medical, Deloitte Consulting - Healthcare & Life Sciences, and Ascension Orthopedics, as well as sales, marketing and business development roles at TissueLink Surgical, Serono Laboratories and Wyeth Pharmaceuticals.

Mr Malik has a Bachelor of Science (Marketing) from Southern Illinois University, USA.

**Chief Financial Officer: Jacqueline Gray**

Ms Gray is a chartered accountant and has more than 20 years' executive experience in both Perth and London, driving the implementation of strategy, meaningful business reporting and a sound governance framework.

She has served as the Chief Financial Officer for a range of ASX-listed and privately-owned businesses, managing revenues in excess of \$100 million.

Ms Gray joins Proteomics International from digital marketing and ecommerce agency RooLife Group, having previously held senior leadership positions at Velpic, City Farmers, Morrison, Sungrid and the West Australian Community Foundation. She has also worked for global companies including the Economist Group, BBC Worldwide, HealthCare of Australia and Arthur Andersen.

Ms Gray holds a Bachelor of Business (Accounting) from Edith Cowan University and a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

ENDS

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Corporate Advisor & Investor Relations  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@euroz.com](mailto:kmoss@euroz.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)